Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Biodexa Pharmaceuticals / Equity Bottom-Up

<ul>
<li>We are initiating coverage of Biodexa Pharmaceuticals PLC (BDRX) with a valuation of $7.00.</li>
<li>Biodexa is a clinical-stage GI oncology company with two core assets: MTX240 and MTX230.</li>
<li>MTX240 offers a novel approach to treating gastrointestinal stromal tumors (GIST) while MTX230 is in a Phase 3 study for the prevention of familial adenomatous polyposis (FAP).</li>
</ul>


We are initiating coverage of Biodexa Pharmaceuticals PLC (BDRX) with a valuation of $7.00.
Biodexa is a clinical-stage GI oncology company with two core assets: MTX240 and MTX230.
MTX240 offers a novel approach to treating gastrointestinal stromal tumors (GIST) while MTX230 is in a Phase 3 study for the prevention of familial adenomatous polyposis (FAP).


BDRX:  Initiating Coverage of Biodexa Pharmaceuticals